Integer (ITGR) Scheduled to Post Earnings on Thursday

Integer (NYSE:ITGR) is scheduled to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of $1.12 per share for the quarter. Integer has set its FY24 guidance at $5.01-5.43 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. The business had revenue of $413.15 million during the quarter, compared to the consensus estimate of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. The business’s revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.11 EPS. On average, analysts expect Integer to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Integer Stock Up 0.0 %

ITGR stock opened at $116.65 on Tuesday. The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. The company’s 50-day moving average price is $112.03 and its 200 day moving average price is $99.05. Integer has a 52 week low of $69.40 and a 52 week high of $121.53. The company has a market cap of $3.91 billion, a P/E ratio of 43.36, a P/E/G ratio of 1.61 and a beta of 1.10.

Analyst Ratings Changes

Several brokerages have recently commented on ITGR. Benchmark boosted their price target on Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. KeyCorp boosted their target price on Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 9th. Bank of America raised Integer from a “neutral” rating to a “buy” rating and upped their target price for the company from $105.00 to $135.00 in a report on Monday, April 15th. Finally, CL King assumed coverage on Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 price target for the company. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.